Andreas Baumann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andreas Baumann has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
Guenter Blaich
AbbVie GmbH, Ludwigshafen, Germany
3 shared publicationsHartmut Blode
3 shared publicationsJay Tibbitts
UCB Celltech, Slough, UK
3 shared publicationsJennifer Sims
Integrated Biologix GmbH, Basel, Switzerland
3 shared publicationsLolke de Haan
MedImmune, Cambridge, UK
3 shared publicationsRasoul S. Kerdar
3 shared publications
Latest Publications
- Open Access
- 19 November 2019
- Published by Wiley in Haemophilia
- Vol. 26 (1) , E11-E13
PEGylated biologics in haemophilia treatment: Current understanding of their long‐term safety
- 19 November 2019
- Published by Wiley in Haemophilia
- Vol. 26 (1) , E11-E13
Open AccessPEGylated biologics in haemophilia treatment: Current understanding of their long‐term safety
- Open Access
- 1 March 2019
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 130, 11-20
Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction
- 1 March 2019
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 130, 11-20
Open AccessPharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction
- 28 January 2018
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 94, 91-100
Biotherapeutics in non-clinical development: Strengthening the interface between safety, pharmacokinetics-pharmacodynamics and manufacturing
- 28 January 2018
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 94, 91-100
Biotherapeutics in non-clinical development: Strengthening the interface between safety, pharmacokinetics-pharmacodynamics and manufacturing
- Open Access
- 17 May 2017
- Published by Springer Nature in The AAPS Journal
- Vol. 19 (4) , 1186-1195
Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys
BAY 1093884 is a fully human monoclonal antibody against the tissue factor pathway inhibitor (TFPI) in development as prophylaxis in patients with hemophilia with or without inhibitors. In vitro, BAY 1093884 binds to human, mouse, and monkey TFPI. The objective of this study was to find a pharmacodynamic (PD) biomarker after administration of BAY 1093884 to normal monkeys. In monkey plasma, BAY 1093884 exhibited an IC50 (concentration that inhibits 50%) of 4.65 and 6.19 nM for free TFPI and diluted prothrombin time (dPT), respectively. The BAY 1093884 pharmacokinetic (PK) profile and its PD effects on dPT and free TFPI levels were assessed after intravenous and subcutaneous administration of BAY 1093884 (5 and 20 mg/kg) to female cynomolgus monkeys. Free TFPI concentrations in plasma decreased rapidly and increased to baseline in a dose-dependent manner. dPT clotting time was shortened and correlated with free TFPI levels and drug concentration in plasma, demonstrating the relationship between PD activities (dPT clotting time and free TFPI levels) and drug concentration. BAY 1093884 exhibited nonlinear PK, and a target-mediated drug disposition model was used to characterize the BAY 1093884 versus TFPI concentration–response relationship. We concluded that a mechanism-based PK/PD binding model could be useful for predicting human response to BAY 1093884. For the first-in-human study, measurement of free TFPI will be included as part of the dose-escalation design.
- 17 May 2017
- Published by Springer Nature in The AAPS Journal
- Vol. 19 (4) , 1186-1195
Open AccessMechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys
BAY 1093884 is a fully human monoclonal antibody against the tissue factor pathway inhibitor (TFPI) in development as prophylaxis in patients with hemophilia with or without inhibitors. In vitro, BAY 1093884 binds to human, mouse, and monkey TFPI. The objective of this study was to find a pharmacodynamic (PD) biomarker after administration of BAY 1093884 to normal monkeys. In monkey plasma, BAY 1093884 exhibited an IC50 (concentration that inhibits 50%) of 4.65 and 6.19 nM for free TFPI and diluted prothrombin time (dPT), respectively. The BAY 1093884 pharmacokinetic (PK) profile and its PD effects on dPT and free TFPI levels were assessed after intravenous and subcutaneous administration of BAY 1093884 (5 and 20 mg/kg) to female cynomolgus monkeys. Free TFPI concentrations in plasma decreased rapidly and increased to baseline in a dose-dependent manner. dPT clotting time was shortened and correlated with free TFPI levels and drug concentration in plasma, demonstrating the relationship between PD activities (dPT clotting time and free TFPI levels) and drug concentration. BAY 1093884 exhibited nonlinear PK, and a target-mediated drug disposition model was used to characterize the BAY 1093884 versus TFPI concentration–response relationship. We concluded that a mechanism-based PK/PD binding model could be useful for predicting human response to BAY 1093884. For the first-in-human study, measurement of free TFPI will be included as part of the dose-escalation design.
- 1 September 2016
- Published by Elsevier in Drug Discovery Today: Technologies
- Vol. 21-22, 95-102
Leverage nonclinical development of bispecifics by translational science
- 1 September 2016
- Published by Elsevier in Drug Discovery Today: Technologies
- Vol. 21-22, 95-102
Leverage nonclinical development of bispecifics by translational science
- 27 August 2016
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 80, S1-S14
Non-clinical Safety Evaluation of Biotherapeutics – Challenges, Opportunities and new Insights
- 27 August 2016
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 80, S1-S14
Non-clinical Safety Evaluation of Biotherapeutics – Challenges, Opportunities and new Insights
- 1 October 2015
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 73 (1) , 265-275
Nonclinical safety testing of biopharmaceuticals – Addressing current challenges of these novel and emerging therapies
- 1 October 2015
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 73 (1) , 265-275
Nonclinical safety testing of biopharmaceuticals – Addressing current challenges of these novel and emerging therapies
- Open Access
- 3 August 2015
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 43 (7) , 959-983
PEGylated Biopharmaceuticals
PEGylation (the covalent binding of one or more polyethylene glycol molecules to another molecule) is a technology frequently used to improve the half-life and other pharmaceutical or pharmacological properties of proteins, peptides, and aptamers. To date, 11 PEGylated biopharmaceuticals have been approved and there is indication that many more are in nonclinical or clinical development. Adverse effects seen with those in toxicology studies are mostly related to the active part of the drug molecule and not to polyethylene glycol (PEG). In 5 of the 11 approved and 10 of the 17 PEGylated biopharmaceuticals in a 2013 industry survey presented here, cellular vacuolation is histologically observed in toxicology studies in certain organs and tissues. No other effects attributed to PEG alone have been reported. Importantly, vacuolation, which occurs mainly in phagocytes, has not been linked with changes in organ function in these toxicology studies. This article was authored through collaborative efforts of industry toxicologists/nonclinical scientists to address the nonclinical safety of large PEG molecules (>10 kilo Dalton) in PEGylated biopharmaceuticals. The impact of the PEG molecule on overall nonclinical safety assessments of PEGylated biopharmaceuticals is discussed, and toxicological information from a 2013 industry survey on PEGylated biopharmaceuticals under development is summarized. Results will contribute to the database of toxicological information publicly available for PEG and PEGylated biopharmaceuticals.
- 3 August 2015
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 43 (7) , 959-983
Open AccessPEGylated Biopharmaceuticals
PEGylation (the covalent binding of one or more polyethylene glycol molecules to another molecule) is a technology frequently used to improve the half-life and other pharmaceutical or pharmacological properties of proteins, peptides, and aptamers. To date, 11 PEGylated biopharmaceuticals have been approved and there is indication that many more are in nonclinical or clinical development. Adverse effects seen with those in toxicology studies are mostly related to the active part of the drug molecule and not to polyethylene glycol (PEG). In 5 of the 11 approved and 10 of the 17 PEGylated biopharmaceuticals in a 2013 industry survey presented here, cellular vacuolation is histologically observed in toxicology studies in certain organs and tissues. No other effects attributed to PEG alone have been reported. Importantly, vacuolation, which occurs mainly in phagocytes, has not been linked with changes in organ function in these toxicology studies. This article was authored through collaborative efforts of industry toxicologists/nonclinical scientists to address the nonclinical safety of large PEG molecules (>10 kilo Dalton) in PEGylated biopharmaceuticals. The impact of the PEG molecule on overall nonclinical safety assessments of PEGylated biopharmaceuticals is discussed, and toxicological information from a 2013 industry survey on PEGylated biopharmaceuticals under development is summarized. Results will contribute to the database of toxicological information publicly available for PEG and PEGylated biopharmaceuticals.
- 1 October 2014
- Published by Elsevier in Drug Discovery Today
- Vol. 19 (10) , 1623-1631
Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?
- 1 October 2014
- Published by Elsevier in Drug Discovery Today
- Vol. 19 (10) , 1623-1631
Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?
- 1 July 2014
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 69 (2) , 226-233
New challenges and opportunities in nonclinical safety testing of biologics
- 1 July 2014
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 69 (2) , 226-233
New challenges and opportunities in nonclinical safety testing of biologics